RENX vs. KOO, COG, FDBK, INHC, TRLS, IQAI, DVRG, SENS, EMIS, and CRW
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Kooth (KOO), Cambridge Cognition (COG), Feedback (FDBK), Induction Healthcare Group (INHC), Trellus Health (TRLS), IQ-AI (IQAI), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry.
Renalytix vs.
Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
Kooth presently has a consensus target price of GBX 583.33, indicating a potential upside of 286.57%. Given Kooth's stronger consensus rating and higher possible upside, research analysts plainly believe Kooth is more favorable than Renalytix.
Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.
Kooth has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
In the previous week, Kooth's average media sentiment score of 0.59 beat Renalytix's score of 0.00 indicating that Kooth is being referred to more favorably in the media.
65.0% of Kooth shares are held by institutional investors. Comparatively, 28.4% of Renalytix shares are held by institutional investors. 17.3% of Kooth shares are held by insiders. Comparatively, 35.7% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Kooth has a net margin of 7.89% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Kooth's return on equity.
Renalytix received 12 more outperform votes than Kooth when rated by MarketBeat users. However, 91.67% of users gave Kooth an outperform vote while only 74.19% of users gave Renalytix an outperform vote.
Summary
Kooth beats Renalytix on 12 of the 17 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
This page (LON:RENX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free RENX Stock Alerts